公开(公告)号：US12029724B2

公开(公告)日：2024-07-09

申请号：US16090360

申请日：2017-04-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Makoto Asano ,  Junji Matsui

IPC: A61K31/357 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K31/357 ,  A61K9/127 ,  A61P35/00

Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190111022A1

公开(公告)日：2019-04-18

申请号：US16090360

申请日：2017-04-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Makoto Asano ,  Junji Matsui

IPC: A61K31/357 ,  A61K9/127 ,  A61P35/00

Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.